OIPE 13 2001

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperbork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for Form 14498 TO (Modified)
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Shiret

	Complete if Known					
Application Number:	09/899,780					
Filing Date:	July 5, 2001					
First Named Inventor:	Gary W. Wood					
Group Art Unit:	1642					
Examiner Name:	Hot yet assigned - Alana M. Harris					
Attorney Docket Number.	70012590-04					

		OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS AND INFORMATION								
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2							
aun	,	David N. Liebowitz, M.D., Ph.D., and Carl H. June, M.D., "Recent Advances in Adoptive Immunotherap," American Society of Clinical Oncology, 1092-9118/99:302-312 (1999).								
		Gregory E. Plautz, M.D. et al., "Systemic T Cell Adoptive Immunotherapy of Malignant Gliomas," J Neurosurg., 89:42-51 (1998).								
		Alfred E. Chang and Suyu Shu, "Current Status of Adoptive Immunotherapy of Cancer," Crit. Rev. Oncol. Hem., 22:213-228 (1996).								
		Alfred E. Chang et al., "Adoptive Immunotherapy With Vaccine-Primed Lymph Node Cells Secondarily Activated With Anti-CD3 and Interleukin-2," J. of Clin. Oncol., 15:796-807 (1997).								
		Jan B. Vermorken et al., "Active Specific Immunotherapy for State II and State III Human Colon Cancer: a Randomised Trial," The Lancet, 353:345-350 (1999).								
		Alfred E. Change et al., "Clinical Observations on Adoptive Immunotherapy With Vaccine-Primed T-Lymphocytes Secondarily Sensitized to Tumor in Vitro," Can. Res., 53:1043-1050 (1993).								
		Frank P. Holladay et al., "Autologous Tumor Cell Vaccination Combined With Adoptive Cellular Immunotherapy in Patients with Grade III/IV Astrocytoma," J. NeuroOncol., 27:179-189 (1996).								
		Stanley P. L. Leong et al., "Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) and Autologous Melanoma Vaccine Mediate Tumor Regression in Patients with Metastatic Melanoma," Journal of Immunotherapy, 22(2):166-174 (1999).								
		Gregory E. Plautz et al., "T-Cell Adoptive Immunotherapy of Metastatic Renal Cell Carcinoma," Urology, 54(4):617-624 (1999).								
	<u>.</u> -	Maurizio Bendandi et al., "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma," Nature Medicine, 5:1171-1177 (1999).								
V		Kruse and Beck, "Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours," Biotechnol. Appl. Biochem, 25:197-205 (1997).								
			_							

Examiner	Allis All:	Date	PANNIAKU	v 13, 7073
Signature	MINTURUS	Considered	"AMUULU	(1)000
0.3			7/	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10-21-1997

03-10-1998

03-17-1998

06-16-1998

		Complete if Known
Substitute for Form 1449A/PTO	Application Number:	09/899,780
INFORMATION DISCLOSURE	Filing Date:	July 5, 2001
STATEMENT BY APPLICANT	First Named Inventor:	Gary W. Wood
(use as many sheets as necessary)	Group Art Unit:	1642
(ass as many ansons as necessary)	Examiner Name:	Not yot assigned Alama M. Harris P

- 1						Examine Name.	Liter for assigned	WILL IN FIRM LIDE LIDE
	She	ęt	1	0	f 2	Attorney Docket Number:	70012590-04	<u>'</u>
						U. S. PATENT DOCUMENTS		
Examiner C		Cite	N	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines Where Relevant
Initials*	No.1	lumber		Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
Ta	M		7	5,126,132		Rosenberg	06-30-1992	
	7		3	5,290,551		Berd	03-01-1994	
	1	3 2		5,443,983		Ochoa, et al.	08-22-1995	
П	Mr	3 0		5,484,596		Hanna, Jr., et al.	01-16-1996	
	1		Į,	5,637,483		Dranoff, et al.	06-10-1997	
	丁		1	5,650,156		Grinstaff et al.	07-22-1997	

Bonnem, et al.

Ochoa, et al.

Babbitt, et al.

Terman

5,679,356

5,725,855

5,728,388

5,766,920

Examiner

Signature

				FORE	GN PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docum	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			WO 97/05239		CELLTHERAPY, INC.	02-13-1997		L
								╀
								╁
								T
								L
								╀
								╀
						- 		-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

¹Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.